Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPOS: KER-012 in Pulmonary Arterial Hypertension
NCT05975905Phase 2Terminated
- Sponsor
- Keros Therapeutics
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
A Phase 2 trial of cibotercept in pulmonary arterial hypertension (PAH), sponsored by Keros Therapeutics. Started Oct 2023; status: terminated.
02
Drugs
cibotercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05975905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975905.